Results 151 to 160 of about 749,010 (351)

Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis–Associated Interstitial Lung Disease

open access: yesArthritis Care &Research, EarlyView.
Objective A leading cause of death among patients with scleroderma (SSc), interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M. Padilla   +13 more
wiley   +1 more source

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England   +9 more
wiley   +1 more source

Comparison of pulmonary function test, diffusion capacity, blood gas analysis and CT scan in patients with and without persistent respiratory symptoms following COVID-19 [PDF]

open access: gold, 2022
Antje Lehmann   +10 more
openalex   +1 more source

Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis

open access: yesArthritis Care &Research, Accepted Article.
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan   +7 more
wiley   +1 more source

Can 1st and 6th month pulmonary function test follow-ups give an idea about the long-term respiratory effects of COVID-19 pneumonia? [PDF]

open access: diamond, 2022
Serkan Emre Eroğlu   +7 more
openalex   +1 more source

Financial Distress and Its Determinants in Rheumatoid Arthritis

open access: yesArthritis Care &Research, EarlyView.
Objective To quantify the degree of financial distress and identify its determinants in adults with rheumatoid arthritis (RA) given the frequent prolonged use of expensive disease‐modifying therapies. Methods We identified adults enrolled in the FORWARD databank with either RA or noninflammatory musculoskeletal disease (NIMSKD) completing the ...
Amber Brown Keebler   +5 more
wiley   +1 more source

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

open access: yesArthritis Care &Research, EarlyView.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung   +7 more
wiley   +1 more source

AN ANALYSIS OF OCCUPATIONAL HEALTH IN PORK PRODUCTION [PDF]

open access: yes
The rapid expansion of large-scale pork production has been accompanied by increasing concerns regarding potential detrimental consequences of environmental hazards on the health of producers.
James Kliebenstein   +2 more
core   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy